{
  "consolidation_metadata": {
    "timestamp": "2025-10-04T15:07:18.349913",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "picos",
    "data_split": "test",
    "total_consolidated_picos": 92,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_picos": [
    {
      "Population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "adults with HCC in Barcelona Clinic Liver Cancer (BCLC) stage B or C who did not receive any prior systemic therapy for the advanced or inoperable disease. Hepatic cirrhosis of any aetiology was not an exclusion criterion. Patients in BCLC stage B had to be ineligible for transarterial chemoembolization (TACE). Further inclusion criteria were Child-Pugh stage A and an Eastern Cooperative Oncology Group – Performance Status (ECOG-PS) score of 0 or 1.",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE + Sorafenib",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE + Sorafenib"
      }
    },
    {
      "Population": "patients with advanced HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE + sorafenib",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE + sorafenib"
      }
    },
    {
      "Population": "HCC patients with PVT",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "HCC patients with PVT",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "local hepatic therapies",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "local hepatic therapies"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "transarterial chemoembolization",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "transarterial chemoembolization"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "transarterial embolization",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "transarterial embolization"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radiotherapy",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radiotherapy"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "supportive care",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "supportive care"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "systemic chemotherapy"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radiofrequency ablation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radiofrequency ablation"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "microwave ablation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "microwave ablation"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "other ablations (laser ablation, cryoablation, HIFU, irreversible electroporation)",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "other ablations (laser ablation, cryoablation, HIFU, irreversible electroporation)"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "alcohol injection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "alcohol injection"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "acetic acid injection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "acetic acid injection"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "liver resection",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "liver resection"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "liver transplantation",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "liver transplantation"
      }
    },
    {
      "Population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radiotherapy (stereotactic body radiotherapy or radioembolisation)",
      "Countries": [
        "AT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable primary hepatocellular carcinoma (HCC) who are not candidates for surgical resection or liver transplantation",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radiotherapy (stereotactic body radiotherapy or radioembolisation)"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "treatment naive adult (aged ≥18 years) patients with advanced, unresectable or metastatic hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK",
        "ES",
        "FR",
        "PT",
        "SE"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 7,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced HCC and adult patients with inoperable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "DK"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced HCC and adult patients with inoperable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adults with advanced or unresectable HCC in adults who have not had previous systemic treatment, only if: • they have Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "most patients with advanced hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "EN"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "most patients with advanced hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "ES",
        "FR"
      ],
      "Source_Types": [
        "hta_submission",
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "Patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Patients aged 18 years or older and diagnosed with locally advanced or metastatic and/ or unresectable HCC with histological/ cytological confirmation or clinical features consistent with the American Association for the Study of the Liver (AASLD) criteria in cirrhotic patients",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "advanced or unresectable hepatocellular carcinoma that has not previously been treated with any other systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced and/ or unresectable hepatocarcinoma, Child-Pugh EMI, in the absence of grade 0 or grade 3-4",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced and/ or unresectable hepatocarcinoma, Child-Pugh EMI, in the absence of grade 0 or grade 3-4",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with locally advanced, unresectable or metastatic CHC, for which they had not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with locally advanced, unresectable or metastatic CHC, for which they had not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with locally advanced, unresectable or metastatic CHC, for which they had not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with locally advanced, unresectable or metastatic CHC, for which they had not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "Stage D or terminal BCLC includes patients with Child- Pugh C or Child-Pugh B with decompensations associated with poor prognosis such as refractory ascites, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis, etc. They are characterised by deterioration of general condition and/or severely impaired hepatic function with median survival not exceeding four months and where the only therapeutic option is best supportive care (8-10 years)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "Stage D or terminal BCLC includes patients with Child- Pugh C or Child-Pugh B with decompensations associated with poor prognosis such as refractory ascites, recurrent hepatic encephalopathy, spontaneous bacterial peritonitis, etc. They are characterised by deterioration of general condition and/or severely impaired hepatic function with median survival not exceeding four months and where the only therapeutic option is best supportive care (8-10 years)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage BCLC B or C) who have not received prior systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with unresectable liver cell carcinomas",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable liver cell carcinomas",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "placebo",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "placebo"
      }
    },
    {
      "Population": "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best care regimen available",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with hepatocellular carcinoma in whom initiation of curative treatment or (continuation) of locoregional or local palliative treatment is not possible or considered medically inappropriate (hepatocell carcinomas)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best care regimen available"
      }
    },
    {
      "Population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resectable hepatocellular carcinoma (HCC) and who have not received any previous systemic therapy",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with hepatocellular carcinoma that was unresectable, diagnosed or histologically, or clinically confirmed according to the Assessment for the Study of Liver Diseases criteria. Modified RECIST criteria were applied. Patients were stage B or C at the Barcelona Liver Cancer Clinic, had a PS or Eastern Cooperative Oncology Group (ECOG) grade score of 0 or 1",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PT"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with hepatocellular carcinoma that was unresectable, diagnosed or histologically, or clinically confirmed according to the Assessment for the Study of Liver Diseases criteria. Modified RECIST criteria were applied. Patients were stage B or C at the Barcelona Liver Cancer Clinic, had a PS or Eastern Cooperative Oncology Group (ECOG) grade score of 0 or 1",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Tecentriq (atezolizumab) plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Tecentriq (atezolizumab) plus bevacizumab"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "adult patients with advanced or non-resettable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Lenvima (lenvatinib)",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "adult patients with advanced or non-resettable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Lenvima (lenvatinib)"
      }
    },
    {
      "Population": "patients with HCC having a non viral etiology",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Tecentriq plus bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "hta_submission"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with HCC having a non viral etiology",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Tecentriq plus bevacizumab"
      }
    },
    {
      "Population": "patients with HCC with evidence of a survival benefit from TACE versus supportive therapy (BSC)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with HCC with evidence of a survival benefit from TACE versus supportive therapy (BSC)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "patients with HCC with evidence of a survival benefit from TACE versus supportive therapy (BSC)",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with HCC with evidence of a survival benefit from TACE versus supportive therapy (BSC)",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "patients with HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "conventional TACE",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "conventional TACE"
      }
    },
    {
      "Population": "patients with HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "drug-eluting TACE",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "drug-eluting TACE"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma and with an ECOG status of 0 1 points",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "Sorafenib",
      "Countries": [
        "AT",
        "DE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 2,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma and with an ECOG status of 0 1 points",
        "intervention": "Medicine X (under assessment)",
        "comparator": "Sorafenib"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "arterial chemoembolization",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "arterial chemoembolization"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radioactive Iodine 131 treatment",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radioactive Iodine 131 treatment"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "systemic chemotherapy (doxorubicin or cisplatin)",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "systemic chemotherapy (doxorubicin or cisplatin)"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "hormonal therapy with tamoxifen",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "hormonal therapy with tamoxifen"
      }
    },
    {
      "Population": "patients with unresectable HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "subcutaneous octreotide therapy",
      "Countries": [
        "BE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "subcutaneous octreotide therapy"
      }
    },
    {
      "Population": "patients with advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "BSC best supportive care",
      "Countries": [
        "ES"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced disease, systemic treatment should be offered to patients with ECOG/PS 0-1 and Child–Pugh class A",
        "intervention": "Medicine X (under assessment)",
        "comparator": "BSC best supportive care"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab plus bevacizumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab plus bevacizumab"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "radioembolization",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "radioembolization"
      }
    },
    {
      "Population": "patients with unresectable hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "chemoembolization",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with unresectable hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "chemoembolization"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma who progressed on sorafenib treatment",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma who progressed on sorafenib treatment",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced and progressing hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced and progressing hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations after sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations after sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma previously treated with sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab plus ipilimumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma previously treated with sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab plus ipilimumab"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma previously treated with sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pembrolizumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma previously treated with sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pembrolizumab"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nivolumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma",
        "intervention": "Medicine X (under assessment)",
        "comparator": "nivolumab"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma and baseline AFP over 400 ng/mL",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma and baseline AFP over 400 ng/mL",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma in CHILD B cirrhotic patients",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pravastatin",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma in CHILD B cirrhotic patients",
        "intervention": "Medicine X (under assessment)",
        "comparator": "pravastatin"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma in CHILD B cirrhotic patients",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib and pravastatin",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma in CHILD B cirrhotic patients",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib and pravastatin"
      }
    },
    {
      "Population": "patients with advanced hepatocellular carcinoma in CHILD B cirrhotic patients",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "best supportive care",
      "Countries": [
        "FR"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced hepatocellular carcinoma in CHILD B cirrhotic patients",
        "intervention": "Medicine X (under assessment)",
        "comparator": "best supportive care"
      }
    },
    {
      "Population": "cirrhotic (max Child-Pugh B) patients with unresectable M0 multi-nodular HCC, in the absence of portal thrombosis",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "TACE",
      "Countries": [
        "IT"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "cirrhotic (max Child-Pugh B) patients with unresectable M0 multi-nodular HCC, in the absence of portal thrombosis",
        "intervention": "Medicine X (under assessment)",
        "comparator": "TACE"
      }
    },
    {
      "Population": "patients with (not locally treatable) HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab with bevacizumab",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with (not locally treatable) HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab with bevacizumab"
      }
    },
    {
      "Population": "patients with (not locally treatable) HCC",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "transarterial radioembolization (TARE)",
      "Countries": [
        "NL"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with (not locally treatable) HCC",
        "intervention": "Medicine X (under assessment)",
        "comparator": "transarterial radioembolization (TARE)"
      }
    },
    {
      "Population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucyrumab",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients previously treated with Sorafenib with AFP ≥ 400 ng/ ml",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucyrumab"
      }
    },
    {
      "Population": "patients who are well tolerant of sorafenib",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients who are well tolerant of sorafenib",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "leninivat",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "leninivat"
      }
    },
    {
      "Population": "second-line patients who have previously received bevacizumab with atezolizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "PO"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "second-line patients who have previously received bevacizumab with atezolizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) without contraindications to the medicinal products",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "atezolizumab and bevacizumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) without contraindications to the medicinal products",
        "intervention": "Medicine X (under assessment)",
        "comparator": "atezolizumab and bevacizumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "tremelimumab-durvalumab combination",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) when combination therapy is inappropriate",
        "intervention": "Medicine X (under assessment)",
        "comparator": "tremelimumab-durvalumab combination"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma with good functional status (WHO PS 0-1) with good liver function (Child Pugh A) who cannot be offered atezolizumab, bevacizumab or tremelimumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma following the progress of first line treatment with TKI",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "lenvatinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "lenvatinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "sorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "regorafenib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "regorafenib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "cabozantinib",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "cabozantinib"
      }
    },
    {
      "Population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "ramucirumab",
      "Countries": [
        "SE"
      ],
      "Source_Types": [
        "clinical_guideline"
      ],
      "Source_Refs": [],
      "Occurrence_Count": 1,
      "Grouping_Key": {
        "population": "patients with advanced or unresectable hepatocellular carcinoma in the second line after atezolizumab-bevacizumab",
        "intervention": "Medicine X (under assessment)",
        "comparator": "ramucirumab"
      }
    }
  ]
}